Fresenius Medical Care AG (FRA:FME)
Germany · Delayed Price · Currency is EUR | Market Cap | 10.25B -18.7% |
| Revenue (ttm) | 19.43B -0.5% |
| Net Income | 937.78M +42.9% |
| EPS | 3.34 +50.0% |
| Shares Out | n/a |
| PE Ratio | 10.93 |
| Forward PE | 10.07 |
| Dividend | 1.49 (3.87%) |
| Ex-Dividend Date | May 22, 2026 |
| Volume | n/a |
| Open | 38.53 |
| Previous Close | 39.62 |
| Day's Range | 38.53 - 38.53 |
| 52-Week Range | 34.60 - 47.50 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 3, 2026 |
About Fresenius Medical Care AG
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient’s residence; and dialysis services under contract to hospitals in the United States for the hospital... [Read more]
Financial Performance
In 2025, Fresenius Medical Care AG's revenue was 19.63 billion, an increase of 1.51% compared to the previous year's 19.34 billion. Earnings were 978.37 million, an increase of 81.88%.
Financial StatementsNews
EQS-PVR: Fresenius Medical Care AG: Publication of acquisition or disposal in respect of own shares according Sec. 40 para. 1 sent. 2 WpHG
EQS Voting Rights Announcement: Fresenius Medical Care AG Fresenius Medical Care AG: Publication of acquisition or disposal in respect of own shares according Sec. 40 para. 1 sent. 2 WpHG 10.09.2026 /...
Fresenius Medical Care Becomes Oversold (FMS)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a tec...
Can Fresenius Medical's 5008X Rollout Drive the Next Growth Phase?
Fresenius Medical is scaling its 5008X rollout across U.S. clinics, creating growth potential despite volume, reimbursement and rollout-cost pressures.
EQS-PVR: Fresenius Medical Care AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Fresenius Medical Care AG Fresenius Medical Care AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Eu...
Fresenius Cuts Fresenius Medical Care Stake, Raises About €300 Mln
(RTTNews) - Fresenius SE & Co. KGaA (FRE.DE) announced that it has agreed to sell approximately 7.8 million shares in Fresenius Medical Care AG (FMS), representing about 2.9% of the dialysis company's...
3 Cheap International Stocks to Buy
These stocks have economic moats and look attractive today.
EQS-CMS: Fresenius Medical Care AG : Release of a capital market information
EQS Post-admission Duties announcement: Fresenius Medical Care AG / Disclosure pursuant to Art. 5 para. 1 lit. b) of Regulation (EU) No. 596/2014 Fresenius Medical Care AG : Release of a capital marke...
Fresenius Medical Care (FMS) Q2 2026 Earnings Call Transcript
U.S. referral execution gap offset by strong margin expansion and transformation savings.
Fresenius Medical price target raised to $25.80 from $25.50 at Bernstein
Bernstein analyst Susannah Ludwig raised the firm’s price target on Fresenius Medical (FMS) to $25.80 from $25.50 and keeps a Market Perform rating on the shares. The firm notes the…
Fresenius Medical price target lowered to EUR 32.30 from EUR 37.40 at JPMorgan
JPMorgan analyst David Adlington lowered the firm’s price target on Fresenius Medical (FMS) to EUR 32.30 from EUR 37.40 and keeps an Overweight rating on the shares. Published first on…
Fresenius Medical price target lowered to EUR 31 from EUR 32 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Fresenius Medical (FMS) to EUR 31 from EUR 32 and keeps an Underweight rating on the shares.
Fresenius Medical price target lowered to $25 from $26 at Truist
Truist lowered the firm’s price target on Fresenius Medical (FMS) to $25 from $26 and keeps a Hold rating on the shares.
Fresenius Medical Care AG Q2 Sales Increase
BAD HOMBURG VOR DER HOEHE (dpa-AFX) - Fresenius Medical Care AG (FME.DE) reported a profit for second quarter of EUR218 millionThe company's earnings totaled EUR218 million, or EUR0.81 per share. ...
Fresenius Medical Care AG (FMS) Shares Fall 5.0% -- What GF Score of 73 Tells Investors
Fresenius Medical Care AG (FMS) Shares Fall 5.0% -- What GF Score of 73 Tells Investors
Fresenius Medical Care AG & Co. KGaA Q2 Earnings Call Highlights
Fresenius Medical Care AG & Co. KGaA NYSE: FMS reported second-quarter 2026 organic revenue growth of 5% and a 23% increase in operating income at constant currency, while confirming its full-year out...
Fresenius Medical Care Shares Drop After U.S. Treatment Volumes Fall Further
Shares fell, wiping out most of their gains since the start of the year, after the German dialysis specialist reported another decline in U.S. treatment volumes in the second quarter.
Fresenius Medical Care AG Earnings Call Transcript: Q2 2026
Operating income grew 23% year-over-year with margin expansion and strong cash flow, despite U.S. treatment volume headwinds and regulatory challenges in China. A EUR 1 billion share buyback was completed and a second program launched, while guidance for 2026 was confirmed.
Fresenius Medical Care AG Earnings release: Q2 2026
Fresenius Medical Care AG released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Fresenius Medical Care AG Slides: Q2 2026
Fresenius Medical Care AG has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
Fresenius Medical Care AG Quarterly report: Q2 2026
Fresenius Medical Care AG has published its Q2 2026 quarterly earnings report on August 4, 2026.
Dialysis firm FMC's shares slide despite earnings beat as US volumes disappoint again
Fresenius Medical Care shares fell in early trade on Tuesday, as investors looked past a second-quarter profit beat to focus on a fresh disappointment in U.S. patient volumes and the management's de...
Fresenius Medical Care beats quarterly profit estimates, sticks to 2026 outlook
Fresenius Medical Care on Monday reported second-quarter operating income well ahead of market expectations and reaffirmed its full-year outlook, as its cost-cutting programme and favourable U.S. re...
Fresenius Medical downgraded to Underperform from Neutral at BNP Paribas
BNP Paribas downgraded Fresenius Medical (FMS) to Underperform from Neutral with a $19.90 price target The firm expects U.S. dialysis volumes to “stay lower for longer.”
Fresenius Medical price target raised to EUR 41 from EUR 40 at Citi
Citi raised the firm’s price target on Fresenius Medical (FMS) to EUR 41 from EUR 40 and keeps a Neutral rating on the shares.
Fresenius Medical initiated with a Market Perform at Bernstein
Bernstein initiated coverage of Fresenius Medical (FMS) with a Market Perform rating and EUR 44.65 price target Dialysis, particularly in the U.S. where the company is over-indexed, has been a…